1. Home
  2. ACLS vs IMVT Comparison

ACLS vs IMVT Comparison

Compare ACLS & IMVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axcelis Technologies Inc.

ACLS

Axcelis Technologies Inc.

HOLD

Current Price

$166.66

Market Cap

5.0B

Sector

Technology

ML Signal

HOLD

Logo Immunovant Inc.

IMVT

Immunovant Inc.

HOLD

Current Price

$28.77

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACLS
IMVT
Founded
1995
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0B
5.8B
IPO Year
2000
2019

Fundamental Metrics

Financial Performance
Metric
ACLS
IMVT
Price
$166.66
$28.77
Analyst Decision
Buy
Buy
Analyst Count
4
8
Target Price
$101.50
$33.00
AVG Volume (30 Days)
785.7K
1.5M
Earning Date
05-07-2026
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.30
N/A
Revenue
$839,048,000.00
N/A
Revenue This Year
$1.93
N/A
Revenue Next Year
$7.91
N/A
P/E Ratio
$42.89
N/A
Revenue Growth
N/A
N/A
52 Week Low
$55.96
$13.52
52 Week High
$171.61
$30.09

Technical Indicators

Market Signals
Indicator
ACLS
IMVT
Relative Strength Index (RSI) 74.29 57.88
Support Level $77.19 $24.97
Resistance Level N/A $29.67
Average True Range (ATR) 8.30 1.48
MACD 1.97 0.00
Stochastic Oscillator 89.42 66.83

Price Performance

Historical Comparison
ACLS
IMVT

About ACLS Axcelis Technologies Inc.

Axcelis Technologies Inc designs, manufactures, and services ion implantation and other processing equipment used in the fabrication of semiconductor chips. In addition to equipment, the company provides aftermarket lifecycle products and services, including used tools, spare parts, equipment upgrades, maintenance services, and customer training. Geographically, the group has a business presence in North America, Asia Pacific, and Europe, of which key revenue is derived from the Asia Pacific.

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

Share on Social Networks: